期刊
LAB ON A CHIP
卷 18, 期 24, 页码 3733-3749出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c8lc00818c
关键词
-
类别
资金
- NIH [1DP2CA195763, R21CA219225]
- Amberstone Biosciences LLC [AB-208317]
- NATIONAL CANCER INSTITUTE [R21CA219225, DP2CA195763] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001414] Funding Source: NIH RePORTER
Adoptive T cell transfer, in particular TCR T cell therapy, holds great promise for cancer immunotherapy with encouraging clinical results. However, finding the right TCR T cell clone is a tedious, time-consuming, and costly process. Thus, there is a critical need for single cell technologies to conduct fast and multiplexed functional analyses followed by recovery of the clone of interest. Here, we use droplet microfluidics for functional screening and real-time monitoring of single TCR T cell activation upon recognition of target tumor cells. Notably, our platform includes a tracking system for each clone as well as a sorting procedure with 100% specificity validated by downstream single cell reverse-transcription PCR and sequencing of TCR chains. Our TCR screening prototype will facilitate immunotherapeutic screening and development of T cell therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据